Is Context Therapeutics Inc. (CNTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 32.9% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 32.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.2% / 33% | 96.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 32.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.2% / 33% | 96.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -46.4% | |
| Return on Assets (ROA) | -29.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$29M |
| Total Debt | $219,380 |
| Debt-to-Equity | 0.2 |
| Current Ratio | 8.5 |
| Total Assets | $98M |
Price & Trading
| Last Close | $2.54 |
| 50-Day MA | $2.46 |
| 200-Day MA | $1.36 |
| Avg Volume | 1.6M |
| Beta | 2.0 |
|
52-Week Range
$0.49
| |
About Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Context Therapeutics Inc. (CNTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Context Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Context Therapeutics Inc.'s debt ratio?
Context Therapeutics Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.
What are Context Therapeutics Inc.'s key financial metrics?
Context Therapeutics Inc. has a market capitalization of $238M. Return on equity stands at -46.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.